Topic guide
Articles and reference material connected to this topic, organised for clear reading.
Reading path
The world’s best-selling anticoagulants are typically prescribed for use once or twice daily, depending on their indication and dosage. Anthos Therapeutics, a Cambridge, MA, startup launched with $250 million …
Read guide →The U.S. Court of Appeals for the Federal Circuit (CAFC) has decided a key remaining question in Novartis’ favor in its ongoing legal wrangle over how quickly it could bring biosimilars of Amgen drugs to marke…
Read guide →Upon approval albinterferon alfa-2b will be marketed as Zalbin in the U.S. and Joulferon in the rest of world. Human Genome Sciences (HGS) received a $75 million milestone payment from Novartis on successful c…
Read guide →A multi-institutional group of researchers led by Harvard Medical School and the Novartis Institutes for BioMedical Research (NIBR) report that it has created an open-source machine learning tool that identifi…
Read guide →Quadrivalent vaccine generated protective immune responses against serotypes A, C, W135, and Y. Novartis reported positive data from a pivotal clinical trial evaluating its Menveo® meningococcal vaccine in inf…
Read guide →Radius granted the firm an option to the exclusive, worldwide rights excluding Japan. Radius Health granted Novartis an option to obtain an exclusive worldwide license, excluding Japan, to its osteoporosis com…
Read guide →Phase III trial found Tasigna resulted in faster and deeper molecular response and better CCyR. The first Phase III trial to directly compare Novartis’ chronic myeloid leukemia (CML) drugs Tasigna® and Glivec®…
Read guide →QAB149 provided rapid, long-lasting benefits to patients. Initial results from Phase III trials of Novartis’ bronchodilator candidate suggest the drug significantly improves lung function in patients with chro…
Read guide →Although significant progress has been made in identifying and drugging the genetic origins of cancer, far too many oncology patients continue to be treated ineffectively. Existing treatments target many activ…
Read guide →Novartis is making a $100 million, $61.3 per share equity investment in Ionis Pharmaceuticals and will pay Ionis and the latter’s Akcea Therapeutics subsidiary $75 million upfront as part of a worldwide option…
Read guide →When it comes to drugs of abuse, public attention and news headlines continue to focus on opioid addiction: In August, the Intermountain Healthcare hospital chain announced it would reduce the number of opioid…
Read guide →Novartis has exercised its license option for the global development and commercialization of Conatus Pharmaceuticals’ oral pan-caspase inhibitor emricasan, under terms of the firms’ $50 million up-front agree…
Read guide →Initiation triggers a $500,000 payment to Avalon for research support. Avalon Pharmaceuticals initiated the primary screening phase under its drug discovery collaboration with Novartis. The collaboration aims …
Read guide →GSK is selling U.S. rights to the migraine treatment Treximet® (sumatriptan/naproxen sodium) to Pernix Therapeutics Holdings, in a pair of deals that could net the pharma giant and a second company as much as …
Read guide →Roche will make available to the Broad Institute a collection of 300 compounds with various indications in hopes of identifying alternative uses for the drugs using the research institute’s screening technolog…
Read guide →Novartis has agreed to identify and validate next-generation DNA Damage Response (DDR) targets for precision cancer treatments using Artios Pharma’s discovery platform, through a collaboration that could gener…
Read guide →Decision is based on pediatric program in hypertension. Novartis received an additional six months of market exclusivity for its high blood pressure drug, Diovan. The treatment is indicated for use in adults w…
Read guide →Deal includes early clinical-stage compound for hematologic cancers. Celgene is buying Avila Therapeutics for $350 million in cash. The deal could be worth an additional $195 million in milestone payments rela…
Read guide →Therapy is already available in over 70 countries and achieved sales of $118 million in 2009. FDA cleared Novartis’ Zortress® for the prevention of organ rejection in adult kidney transplant patients at low-to…
Read guide →Firms aim to co-develop vaccines for Chinese market and invest in R&D and manufacturing. Novartis has completed its acquisition of 85% of Chinese vaccines firm Zhejiang Tianyuan Bio-Pharmaceutical. The roughly…
Read guide →